NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 5.66 against a street estimate of 5.40 — a beat of 4.8%.
with an average price target of ₹474.00.
| Holder | Stake |
|---|---|
| DSP Small Cap Fund | 7.93% |
| Harit Pragji Shah | 2.67% |
| ICICI Prudential Healthcare Fund | 2.03% |
| Jayshree Harit Shah | 1.78% |
| Document | Date |
|---|---|
| Annual report FY2026 AARTI DRUGS LIMITED - ANNUAL REPORT FY 2025-26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Total Revenue: ₹2,568 crores (consolidated basis) • E | 2026-09-02 |
| Q1 FY27 earnings call AARTI DRUGS LIMITED – Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue (Consolidated): INR 703.6 crores (Q1 FY27) vs INR 590.8 crores (Q1 FY26) – | 2026-08-07 |
| Investor presentation AARTI DRUGS LIMITED – Q1 FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Total Revenue: ₹704 crores in Q1 FY27, up 19% YoY from ₹591 crores in Q1 FY26 • EB | 2026-08-01 |
| Q4 FY26 earnings call AARTI DRUGS LIMITED – Q4 & FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY26 consolidated revenue: INR 721.1 crores (vs INR 678.6 crores in Q4 FY25; | 2026-05-23 |
| Investor presentation · Q4 FY26 AARTI DRUGS LIMITED – Q4 & FY26 INVESTOR PRESENTATION SUMMARY HEADLINE NUMBERS • FY26 Total Revenue: Rs 2,567.7 crore (+7% YoY vs Rs 2,403.4 crore i | 2026-05-16 |
| Quarterly results · Q4 FY26 AARTI DRUGS LIMITED – FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS STANDALONE (Year ended March 31, 2026) • Total Income: ₹2,40,339 lakhs | 2026-05-15 |
| Q3 FY26 earnings call AARTI DRUGS LIMITED – Q3 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue (Consolidated): INR 602.9 crores vs. INR 557.1 crores in Q3 FY25 ( | 2026-02-10 |
| Quarterly results · Q3 FY26 AARTI DRUGS LIMITED – FINANCIAL RESULTS SUMMARY Quarter & Nine Months Ended December 31, 2025 --- HEADLINE NUMBERS • Q3 FY2025-26 Revenue from Oper | 2026-02-03 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹2 / share ex-date Feb 9, 2026 | 2026-02-09 |
| Announcement | Date |
|---|---|
| Interim dividend of Rs. 2 per equity share declared Aarti Drugs Limited's Board of Directors declared an interim dividend of Rs. 2 per equity share on February 03, 2026. An interim dividend is a cash payment distributed to shareholders before | 2026-02-03 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aarti Drugs Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.